Fate Therapeutics Inc. (FATE) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Fate Therapeutics Inc. (NASDAQ: FATE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.08 (-4.15% 1D, market cap $249.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FATE ranks #597 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), FATE carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LCTX (Lineage Cell Therapeutics Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $252.9M) and CABA (Cabaletta Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M). Among the 5-stock peer group, FATE leads on earnings multiple (N/A) while FATE leads on capital efficiency (-35.0% ROIC).
Per FATE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434316), Fate Therapeutics Inc. generated $6.6M in revenue (-51.2% YoY), -$136.3M in net income, and -$112.0M in free cash flow against $318.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 50% of 52W Range • RSI-14 at 45.8 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While FATE currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.28) and Max Pain ($2.18) forces dealer call-delta covering toward $3.39.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Fate Therapeutics Inc. (FATE) dropped -4.15% to $2.08, trading at 50% of its 52-week range ($0.95 – $3.23). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Singapore report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -51.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on FATE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for FATE. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Fate Therapeutics Inc. (FATE) ranks #597 by composite RQD confidence (35/100, grade D-) and #542 by equity capitalization ($249.2M). Within this direct 5-issuer industry benchmark cohort, FATE leads on earnings valuation at N/A trailing P/E, while FATE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. FATE currently leads its immediate peer cohort in composite quantitative strength at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FATE
ACTIVE
Fate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -4.15% | $249.2M | Benchmark Subject |
| LCTX Lineage Cell Therapeutics Inc. | E | 20/100 | — | — | -35.0% | -2.91% | $252.9M | /lctx-vs-fate → |
| CABA Cabaletta Bio Inc. | E | 33/100 | — | — | -35.0% | -4.73% | $256.0M | /caba-vs-fate → |
| LXEO Lexeo Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +2.61% | $257.6M | /lxeo-vs-fate → |
| OCGN Ocugen Inc. | E | 25/100 | — | — | -35.0% | -5.58% | $238.3M | /ocgn-vs-fate → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fate Therapeutics Inc. (FATE) reported GAAP revenue of $6.6M (-51.2% vs. FY2024 revenue of $13.6M , and -89.5% cumulative change since FY2023) , GAAP net income of -$136.3M, operating cash flow of -$106.1M, and free cash flow of -$112.0M (+9.4% YoY). On the balance sheet, FATE closed FY2025 with $318.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.6M | -$136.3M | -$106.1M | -$112.0M | $318.9M | — |
| FY2024 (FY) | 2024-12-31 | $13.6M | -$186.3M | -$122.9M | -$123.6M | $440.7M | — |
| FY2023 (FY) | 2023-12-31 | $63.5M | -$160.9M | -$132.3M | -$132.3M | — | — |
As of 2026-11-03, Fate Therapeutics Inc. (NASDAQ: FATE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.08 (-4.15% 1D, market cap $249.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FATE ranks #597 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), FATE carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LCTX (Lineage Cell Therapeutics Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $252.9M) and CABA (Cabaletta Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M). Among the 5-stock peer group, FATE leads on earnings multiple (N/A) while FATE leads on capital efficiency (-35.0% ROIC).
Per FATE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434316), Fate Therapeutics Inc. generated $6.6M in revenue (-51.2% YoY), -$136.3M in net income, and -$112.0M in free cash flow against $318.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
FATE last traded at $2.08 (-4.15% on volume of 1,064,428 shares), positioning the stock -8.77% below its 50-day simple moving average ($2.28) and +5.58% above its 200-day simple moving average ($1.97). Across its 52-week range of $0.95 to $3.23, FATE sits at the 49.6% percentile with a 14-day RSI of 45.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.82 to $2.34).
Why FATE Stock dropped -4.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, FATE scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 9/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 7/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).
The weakest pillar is Insider Conviction, and the Cash Engine pillar is also low, which together indicate that the company's operating economics and insider-level signals do not currently offer strong support for the stock. The Forensic Balance Sheet pillar is middling rather than distressed: an Altman Z of 2.5 and a Piotroski F of 3/9 sit in a weak-to-mixed zone. Whale flow at 9/20 shows some institutional interest but not conviction at scale. Macro fit at 11/20 reflects a beta of 1.0, meaning the stock is rated as moving in line with the broader market rather than amplifying it.
Fate Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the FY 2025 financials, reported revenue was $6.6M against an operating loss of $-147.7M, and the recent news wire notes the appointment of a senior vice president for commercialization of CAR T-cell therapies. Beyond these references, —
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Analyst consensus rating, price targets from the analyst data section, and holder trades: — The news wire does reference a 12-month price target cut to $6.07 (TradingView, RED), but no analyst consensus rating is provided in the analyst section.
Real-time company headlines, analyst actions, and sector developments for Fate Therapeutics Inc. (FATE) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.
Welcome to the FATE (Fate Therapeutics Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on FATE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Fate Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on FATE, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.17 (52-wk range $0.95 - $3.23), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).